Berry Genomics Co.

Beijing, China

Berry Genomics Co.

Beijing, China
SEARCH FILTERS
Time filter
Source Type

News Article | April 20, 2017
Site: marketersmedia.com

— This report studies DNA Sequencing in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering Illumina Roche Macrogen BGI WuXi AppTec DAAN GENE Novo Gene Berry Genomics Biomarker Majorbio CapitalBio Genomics Anoroad King Med Didan Diagostics ZiXin Da Rui Adicon For more information or any query mail at sales@wiseguyreports.com By types, the market can be split into First Generation DNA Sequencing Second Generation DNA Sequencing Third Generation DNA Sequencing By Application, the market can be split into Oncology DNA Sequencing Life Science DNA Sequencing Emerging Application DNA Sequencing Hereditary Disease Detection DNA Sequencing By Regions, this report covers (we can add the regions/countries as you want) North America China Europe Southeast Asia Japan India Global DNA Sequencing Market Professional Survey Report 2017 1 Industry Overview of DNA Sequencing 1.1 Definition and Specifications of DNA Sequencing 1.1.1 Definition of DNA Sequencing 1.1.2 Specifications of DNA Sequencing 1.2 Classification of DNA Sequencing 1.2.1 First Generation DNA Sequencing 1.2.2 Second Generation DNA Sequencing 1.2.3 Third Generation DNA Sequencing 1.3 Applications of DNA Sequencing 1.3.1 Oncology DNA Sequencing 1.3.2 Life Science DNA Sequencing 1.3.3 Emerging Application DNA Sequencing 1.3.4 Hereditary Disease Detection DNA Sequencing 1.4 Market Segment by Regions 1.4.1 North America 1.4.2 China 1.4.3 Europe 1.4.4 Southeast Asia 1.4.5 Japan 1.4.6 India 2 Manufacturing Cost Structure Analysis of DNA Sequencing 2.1 Raw Material and Suppliers 2.2 Manufacturing Cost Structure Analysis of DNA Sequencing 2.3 Manufacturing Process Analysis of DNA Sequencing 2.4 Industry Chain Structure of DNA Sequencing 3 Technical Data and Manufacturing Plants Analysis of DNA Sequencing 3.1 Capacity and Commercial Production Date of Global DNA Sequencing Major Manufacturers in 2016 3.2 Manufacturing Plants Distribution of Global DNA Sequencing Major Manufacturers in 2016 3.3 R&D Status and Technology Source of Global DNA Sequencing Major Manufacturers in 2016 3.4 Raw Materials Sources Analysis of Global DNA Sequencing Major Manufacturers in 2016 8 Major Manufacturers Analysis of DNA Sequencing 8.1 Illumina 8.1.1 Company Profile 8.1.2 Product Picture and Specifications 8.1.2.1 Product A 8.1.2.2 Product B 8.1.3 Illumina 2016 DNA Sequencing Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.1.4 Illumina 2016 DNA Sequencing Business Region Distribution Analysis 8.2 Roche 8.2.1 Company Profile 8.2.2 Product Picture and Specifications 8.2.2.1 Product A 8.2.2.2 Product B 8.2.3 Roche 2016 DNA Sequencing Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.2.4 Roche 2016 DNA Sequencing Business Region Distribution Analysis 8.3 Macrogen 8.3.1 Company Profile 8.3.2 Product Picture and Specifications 8.3.2.1 Product A 8.3.2.2 Product B 8.3.3 Macrogen 2016 DNA Sequencing Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.3.4 Macrogen 2016 DNA Sequencing Business Region Distribution Analysis 8.4 BGI 8.4.1 Company Profile 8.4.2 Product Picture and Specifications 8.4.2.1 Product A 8.4.2.2 Product B 8.4.3 BGI 2016 DNA Sequencing Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.4.4 BGI 2016 DNA Sequencing Business Region Distribution Analysis 8.5 WuXi AppTec 8.5.1 Company Profile 8.5.2 Product Picture and Specifications 8.5.2.1 Product A 8.5.2.2 Product B 8.5.3 WuXi AppTec 2016 DNA Sequencing Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.5.4 WuXi AppTec 2016 DNA Sequencing Business Region Distribution Analysis 8.6 DAAN GENE 8.6.1 Company Profile 8.6.2 Product Picture and Specifications 8.6.2.1 Product A 8.6.2.2 Product B 8.6.3 DAAN GENE 2016 DNA Sequencing Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.6.4 DAAN GENE 2016 DNA Sequencing Business Region Distribution Analysis 8.7 Novo Gene 8.7.1 Company Profile 8.7.2 Product Picture and Specifications 8.7.2.1 Product A 8.7.2.2 Product B 8.7.3 Novo Gene 2016 DNA Sequencing Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.7.4 Novo Gene 2016 DNA Sequencing Business Region Distribution Analysis 8.8 Berry Genomics 8.8.1 Company Profile 8.8.2 Product Picture and Specifications 8.8.2.1 Product A 8.8.2.2 Product B 8.8.3 Berry Genomics 2016 DNA Sequencing Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.8.4 Berry Genomics 2016 DNA Sequencing Business Region Distribution Analysis 8.9 Biomarker 8.9.1 Company Profile 8.9.2 Product Picture and Specifications 8.9.2.1 Product A 8.9.2.2 Product B 8.9.3 Biomarker 2016 DNA Sequencing Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.9.4 Biomarker 2016 DNA Sequencing Business Region Distribution Analysis 8.10 Majorbio 8.10.1 Company Profile 8.10.2 Product Picture and Specifications 8.10.2.1 Product A 8.10.2.2 Product B 8.10.3 Majorbio 2016 DNA Sequencing Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.10.4 Majorbio 2016 DNA Sequencing Business Region Distribution Analysis 8.11 CapitalBio Genomics 8.12 Anoroad 8.13 King Med 8.14 Didan Diagostics 8.15 ZiXin 8.16 Da Rui 8.17 Adicon For more information or any query mail at sales@wiseguyreports.com ABOUT US: Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of rmaket research reports under these categories and sub-categories. For more information, please visit https://www.wiseguyreports.com


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Non-Invasive Prenatal Testing (NIPT) Market - Analysis and Forecast (2017-2023) (Focus on Test Type, Country Analysis (Test Volume & Value), APAC Countries by Test Type, Patent Landscape, and Competitive Landscape)" report to their offering. Panorama Held the Largest Share of 19% of the Non-Invasive Prenatal Testing (NIPT) Market In Terms of Revenue in 2016, Followed by NIFTY With 16% Non-invasive prenatal testing (NIPT) is an innovative way of screening pregnancies for fetal chromosomal aneuploidies by analyzing fetal cell-free DNA circulating in maternal blood. Amniocentesis, chorionic villus sampling (CVS), maternal serum screening, and nuchal translucency (NT) scan have been the primary diagnostic and screening methods for chromosomal abnormalities. The growth of NIPT market is attributed primarily to a rapid increase in genetic disorders/abnormalities, increase in fetal mortality, adoption of NIPT test in developed countries, and advancement of healthcare technologies. In spite of enormous competition levels that prevails in the industry, the market growth is expected to be propelled by multiple factors such as rising demand for prenatal testing, adoption toward IVF procedures, increasing awareness among parents, and upsurge in the government spending on healthcare. The research study has segmented the entire NIPT market into test value and volume, and geographical region including detail country analysis which enables the user gain a multi-dimensional view of the market. The research report employs an exhaustive and analytical approach to estimate and understand the market thus provides an all-inclusive insight into various forms of developments, market trends and strategies. While underlining the key driving and restraining factors for the NIPT market, the report also provides a comprehensive understanding in terms of competitive landscape, market share analysis, competitor benchmarking (matrices), and their positioning within the global NIPT market. Some of the key player include Roche, Natera, Illumina, LabCorp, LifeCodexx, BGI Diagnostics, Premaitha and Berry Genomics, among others. The following questions have been answered in this report: 6. Global NIPT Market, By Test (Volume and Value) 7. Global NIPT Market, By Geography (Volume and Value) For more information about this report visit http://www.researchandmarkets.com/research/9wr2fs/global


The research study has segmented the entire NIPT market into test value and volume, and geographical region including detail country analysis which enables the user gain a multi-dimensional view of the market. The research report employs an exhaustive and analytical approach to estimate and understand the market thus provides an all-inclusive insight into various forms of developments, market trends and strategies. While underlining the key driving and restraining factors for the NIPT market, the report also provides a comprehensive understanding in terms of competitive landscape, market share analysis, competitor benchmarking (matrices), and their positioning within the global NIPT market. NIPT tests are gaining rapid pace worldwide due to various government supportive programs and schemes. In many countries, the market growth is restrained due to their cultural and ethical attitudes towards this process. However, the government educational programs support and regulations are building a platform for the development of the NIPT market that would benefit their citizens. Countries such as Saudi Arabia, the U.A.E., Turkey, Oman and Iran among others, have economical and infrastructural support but have still not approved these tests in their countries due to the shortage of educational and government development programs. Sequenom, Inc., Natera, Inc., Roche Diagnostics, Illumina, Inc., BGI Diagnostics, LabCorp, LifeCodexx AG and Berry Genomics are the leading players operating in the global NIPT market. With the advent of new market entrants and increasing adoption of NIPT across the world, the competitive landscape of the market is expected to change during the forecast period, wherein players offering cost-effective, accurate, and quicker tests are projected to record a high growth rate. The market is driven by product launches and development strategies followed by partnerships and collaborations. Moreover, established healthcare diagnostic companies are acquiring small market players/new entrants to position themselves in the NIPT market. For example, the recent acquisition of Sequenom Inc. by LabCorp in January 2017 has again showcased the need of acquisition of elementary player of the market. Also, Roche acquired Ariosa Diagnostics in 2014 while Illumina acquired Verinata Health in 2014. Due to the nascent stage of the market, the companies should focus on the development of technologically advanced, highly accurate and cost effective tests which can screen and diagnose numerous disorders in the prenatal market scheme. The existing players should emphasize on the expansion of their business in countries with huge population and high birth rate such as China, India, Brazil, Niger, and other MEA countries. The increasing awareness and need for early diagnosis of genetic disorders will generate a huge market for prenatal tests in the future. The development of pre-implantation diagnosis tests are helping parents in early stage of pregnancy, and is foreseen as a viable opportunity for this market. Key Topics Covered: Executive Summary   1. Report Scope & Methodology 2. Market Overview 3. Market Dynamics 4. Major Chromosomal Aneuploidies 5. Competitive Landscape 6. Global NIPT Market, By Test (Volume and Value) 7. Global NIPT Market, By  Geography (Volume and Value) 8. End User Perception 9. Company Profiles For more information about this report visit http://www.researchandmarkets.com/research/qb6bk2/global Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/research-and-markets---global-non-invasive-prenatal-testing-market-2017-2023-leading-players-are-sequenom-natera-roche-diagnostics-illumina-inc-bgi-diagnostics-labcorp-lifecodexx--berry-genomics-300455165.html


The disclosure claims a method for tracking a sample in a second-generation Deoxyribonucleic acid (DNA) sequencing technology and a detection kit, wherein the method includes the following steps of: 1) incorporating DNA molecular tag with a known sequence into a sample, and obtaining a sequencing sample; 2) sequencing the sequencing sample; 3) screening the molecular tag sequence from the sequencing result of step 2), and comparing with the known sequence of the molecular tag. As the sequencing process of the tag is synchronously implemented during the sequencing process of the DNA molecular, this method can be conveniently operated, and the confusion of the samples caused by manual operation can be found instantly; thereby, this method not only has important significance for the technical research, but also greatly improves the strictness of the clinical detection if applied to the clinical detection.


The invention relates to a kit, a device and a method for detecting the copy number of fetal chromosomes and tumor cell chromosomes. The method for detecting the copy number of fetal chromosomes or tumor cell chromosomes of the invention includes the following steps: collecting maternal plasma or plasma of tumor patient; separating the plasma from blood cells in blood; preparing Deoxyribonucleic Acids (DNA) in the plasma into a sequencing library; sequencing the DNA sequencing library; comparing a sequencing result with a genomic sequence map to determine which chromosome the DNA sequence comes from and the length of each DNA sequence; and calculating the ratio of the DNA segments from the chromosomes to be detected to all DNA segments in the same sample by a sequencing and comparison result of DNA, correcting the ratio according to a GC content of the DNA segments from the chromosomes to be detected, and calculating the variation of the corrected ratio of the DNA segments from the chromosomes to be detected in a sample to be detected, and determining the copy number of the chromosomes to be detected according to degree of variation.


Patent
Berry Genomics Co. | Date: 2012-01-10

The disclosure relates a method and a kit for constructing a plasma Deoxyribonucleic acid (DNA) sequencing library. The method provided by the disclosure includes: extracting a plasma DNA; making the plasma DNA ligate to a sequencing linker, and purifying a ligation product; performing Polymerase Chain Reaction (PCR) amplification for the purified ligation product, purifying the PCR amplification product, and obtaining the plasma DNA sequencing library, wherein, the method does not include the step of performing 5-terminus phosphorylation for the plasma DNA. The kit provided by the disclosure includes: a reagent which ligates a plasma DNA to a sequencing linker, including the sequencing linker, a ligase and a ligation buffer; and reagents and instruments for purifying the ligation product; a reagent which performs PCR amplification for a purified ligation product, and reagents and instruments for purifying the PCR amplification product; wherein, the kit does not include the reagent which performs 5-terminus phosphorylation for the plasma DNA. The disclosure simplifies the construction flow of a plasma DNA sequencing library, simplifies the experimental procedures, and makes the construction of the plasma sample library have lower cost, higher efficiency and faster speed, and is convenient for large-scale application.


Patent
Berry Genomics Co. | Date: 2014-12-16

The present invention discloses a method for non-invasively detecting EGFR gene mutations in subjects, comprising the following steps: designing primers according to EGFR gene exons; extracting plasma DNAs in subjects; connecting the extracted plasma DNAs with tagging linkers; PCR pre-amplifying the tagging linkers connected plasma DNAs; cyclising the pre-amplified DNAs to obtain cyclised DNAs; PCR amplifying the cyclised DNAs using the designed primers; and high throughput sequencing the PCR amplified product and analyzing the EGFR gene mutations. The present invention also discloses a corresponding kit.


The present invention is directed to a method, kit and primers for detecting fetal deafness pathogenic gene mutations. The method of the invention comprises: (a) designing primers according to the pre-determined mutation loci of deafness pathogenic genes; (b) extracting plasma DNAs in a pregnant woman; (c) connecting the extracted plasma DNAs with pre-amplification linkers to obtain connected products; (d) PCR pre-amplifying the connected product to obtain pre-amplified products; (e) cyclizing the pre-amplified products to obtain cyclised DNAs; (f) PCR amplifying the cyclised DNAs using the designed primers to obtain amplified products; and (g) high throughput sequencing the amplified products and analyzing the mutations of the fetal deafness pathogenic genes. The invention can effectively determine whether the pre-determined loci on deafness pathogenic genes have been mutated as well as the mutation type.


The present invention is directed to a method, kit and primers for detecting fetal deafness pathogenic gene mutations. The method of the invention comprises: (a) designing primers according to the pre-determined mutation loci of deafness pathogenic genes; (b) extracting plasma DNAs in a pregnant woman; (c) connecting the extracted plasma DNAs with pre-amplification linkers to obtain connected products; (d) PCR pre-amplifying the connected product to obtain pre-amplified products; (e) cyclizing the pre-amplified products to obtain cyclised DNAs; (f) PCR amplifying the cyclised DNAs using the designed primers to obtain amplified products; and (g) high throughput sequencing the amplified products and analyzing the mutations of the fetal deafness pathogenic genes. The invention can effectively determine whether the pre-determined loci on deafness pathogenic genes have been mutated as well as the mutation type.


The disclosure claims a cleaved Deoxyribonucleic acid (DNA) detection method, a DNA fragment detection kit and use thereof. Wherein, the method includes the steps of: designing primers according to a test site or a test region of the DNA fragment; cyclizing the DNA fragment to obtain acyclized DNA; implementing Polymerase Chain Reaction (PCR) amplification for the cyclized DNA by using the primers; and detecting the PCR amplification product. In the disclosure, by cyclizing the DNA fragment, the amplification can be implemented even if only one PCR primer can match with a template, thus, the adaption range and effective template amount of the primer amplification can be greatly increased, and the detection sensitivity of the DNA fragment can be greatly improved.

Loading Berry Genomics Co. collaborators
Loading Berry Genomics Co. collaborators